- Panitumumab in the treatment of colorectal carcinoma2020 | Publication without faculty affiliation
- Panitumumab in treating patients with advanced metastatic colorectal cancer2012 | Faculty of Medicine in Pilsen
- Panitumumab as first-line treatment of colorectal cancer2019 | Publication without faculty affiliation
- Panitumumab in the first-line treatment of elderly patients - results of the PANDA study2021 | Publication without faculty affiliation
- Panitumumab in metastatic colorectal cancer in combination with chemotherapy2010 | First Faculty of Medicine
- Long-term effect of panitumumab therapy in a patient with primarily generalized colorectal cancer - case report2021 | Publication without faculty affiliation
- Commentary on studies safety and efficacy of panitumumab in metastatic colorectal cancer2009 | First Faculty of Medicine
- Cost-effectiveness Analysis of Panitumumab Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 for First-line Treatment of Patients with Wild-type RAS Metastatic Colorectal Cancer - Czech Republic Model Adaptation2015 | Faculty of Medicine in Pilsen
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. 20062079Publication without faculty affiliation
- Anti-EGFR treatment of colorectal cancer2021 | Publication without faculty affiliation
- Editorial2017 | Faculty of Medicine in Pilsen
- Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients2016 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Central Library of Charles University
- Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC2019 | First Faculty of Medicine
- Hypomagnesemia in cancer patients and possible solutions2021 | Faculty of Medicine in Pilsen
- The effect of chelator type on in vitro receptor binding and stability in Lu-177-labeled cetuximab and panitumumab2014 | Faculty of Pharmacy in Hradec Králové
- Kompletní odpověď primárního tumoru a regionální lymfadenopatie po léčbě panitumumabem pacientky s generalizovaným adenokarcinomem rekta2018 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Options and rationale for reinstituting anti-EGFR therapy in pretreated RAS wild-type advanced colorectal carcinomas2023 | Publication without faculty affiliation
- Possibilities and substantiation of re-treatment with anti-EGFR drugs for pre-treated RAS wild-type advanced colorectal cancers2021 | Publication without faculty affiliation
- Treatment of metastatic colorectal carcinoma - 3rd line and abovePublication without faculty affiliation
- MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab2015 | Publication without faculty affiliation
- Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis2019 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents2019 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay2014 | Faculty of Pharmacy in Hradec Králové
- Anti-EGFR therapy in colorectal carcinoma2017 | Publication without faculty affiliation
- A case study of a patient with advanced, KRAS wild-type colorectal carcinoma, treated with cetuximab2013 | Second Faculty of Medicine
- Pharmacotherapy of metastatic colorectal cancer - current therapeutic options2011 | Faculty of Medicine in Hradec Králové
- Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer2020 | Faculty of Medicine in Pilsen
- Regorafenib monotherapy in pretreated metastatic colorectal cancer (CORRECT): an international, multicenter, randomized, placebo-controlled clinical trial Phase 32013 | Second Faculty of Medicine
- Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis2018 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Efficacy of anti-VEGF therapy with afliberceptem in advanced colorectal cancer2017 | Publication without faculty affiliation